Study selection
Initial literature searches are described in Figure 1. Ultimately,
nineteen DD-related eligible studies were included[2, 12, 16,
26-41]. We searched the literature and finally included six agents of
HIF-PHIs, including Roxadustat[12, 16, 26-30],
Daprodustat[31-35], Vadadustat[2, 36], Molidustat[37, 38,
40], Enarodustat[39], and Desidustat[41]. One of the studies
described two different RCTs of Vadadustat, and both trials compared
Vadadustat and Darbepotin, including respectively incident DD CKD trial
(369 participants) and prevalent DD CKD trial (3554
participants)[2].